The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMW 2019 | MRD in myeloma: an important surrogate for PFS
Bruno Paiva
• 12 Sep 2019
Here, Bruno Paiva, PhD, from the University of Navarra Clinic, Pamplona, Spain, emphasizes how MRD assessment has become an appropriate surrogate for PFS in multiple myeloma. Recorded at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.
